Bradeion (SEPT4) as a Urinary Marker of Transitional Cell Bladder Cancer: A Real-Time Polymerase Chain Reaction Study of Gene Expression

The Journal of Urology, 05/15/2012

Bradeion/SEPT4 transcript levels are significantly increased in patients with transitional cell bladder cancer compared to healthy controls. The preliminary study supports the possible usefulness of Bradeion as a urinary marker of urothelial disease.

Print Article Summary Cat 2 CME Report